This low likelihood, together with the fact that the majority of patients with BRAF V600E-mutant mCRC require an intensive first-line regimen to control the aggressive tumor growth, supports the investigation of EC+mFOLFOX6, and led to the early closure of EC arm enrollment. This evidence concerns the gene BRAF and neoplasm.